MaxCyte, Inc. Change of Auditor (8667K)
December 19 2018 - 1:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 8667K
MaxCyte, Inc.
19 December 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Change of Auditor
Gaithersburg, Maryland - 19 DECEMBER 2018: MaxCyte (LSE: MXCT),
the global cell-based medicines and life sciences company, is
pleased to announce that following the conclusion of a formal
tender process overseen by the Company's audit committee, the
Company has appointed CohnReznick LLP (which ranks among the
largest accounting, tax and business advisory firms in the United
States) as the Company's independent auditor for the financial year
ended 31 December 2018. The appointment of CohnReznick LLP as the
Company's auditor for the financial year ended 31 December 2019
will be subject to approval by the Company's shareholders at the
next Annual General Meeting due to be held in October 2019.
Aronson LLC has confirmed to the Company that it is not aware of
any circumstances connected with its termination as auditor that it
considers should be brought to the attention of the Board,
creditors or shareholders of the Company. MaxCyte would like to
thank Aronson LLC for its many years of service to the Company.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its proprietary cell engineering technology
platform to deliver the advances of cell-based medicine to patients
with high unmet medical needs in a broad range of conditions.
MaxCyte is developing novel CARMA therapies for its own pipeline.
CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for
rapid autologous cell therapy for the treatment of solid cancers.
In addition, through its core business, MaxCyte leverages its Flow
Electroporation(R) Technology to enable its biopharmaceutical
industry partners to advance the development of innovative,
cutting-edge medicines, particularly in cell therapy, including the
use of gene editing tools in the treatment of inherited genetic
diseases and immuno-oncology approaches to treating cancer. MaxCyte
has placed its cutting-edge flow electroporation instruments
worldwide, with all of the top ten global biopharmaceutical
companies, has more than 55 partnered programme licences in cell
therapy including more than 25 licensed for clinical use. With its
robust delivery technology platform, MaxCyte helps its partners to
unlock the full potential of their products. For more information,
visit www.maxcyte.com.
About CohnReznick
CohnReznick LLP ranks among the largest accounting, tax and
business advisory firms in the United States, with a team of over
2,400 professionals and an extensive footprint in 26 cities
worldwide.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPUWASRWWAUAAA
(END) Dow Jones Newswires
December 19, 2018 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024